Main Menu

This technology involves the development of lgG1 Fe variants designed to interact more effectively with the neonatal Fc receptor (FcRn) in a pH-dependent manner. By enhancing this interaction, these variants extend the serum half-life of therapeutic antibodies, reducing the need for frequent administration. This breakthrough holds the potential to make therapeutic antibody treatments more convenient, cost-effective, and accessible for a wide range of diseases.

Trispecific and trivalent binding proteins represent a breakthrough in the battle against HIV infection. These specialized proteins are engineered with four polypeptide chains forming three antigen binding sites, enabling precise targeting of HIV target proteins. Addressing the formidable challenges of HIV treatment, including the virus's high mutation rate and the persistence of viral reservoirs, these binding proteins offer a potential solution to breakthrough infections.

The groundbreaking technology of high-frequency cell mechanics assessment represents a paradigm shift in the field of cell analysis. This innovation enables rapid and non-invasive evaluation of cell health and viability, eliminating the need for cell labeling or modification. By measuring cell viscoelastic properties at high frequencies, it offers real-time insights into the mechanical characteristics of individual cells and entire populations.

This technology includes the NeurEx® mobile application, a groundbreaking tool designed for neurologists to conduct and document neurological examinations efficiently. Deployed on iPads, it integrates with a secure, cloud-based database, automating the computation of four key disability scales used in neuroimmunology. The app's robust design enables precise mapping of neurological deficits, blending spatial distribution with quantitative assessments.

The technology in focus encompasses a novel suite of synthetic peptide immunogens, collaboratively developed by leading institutions, aimed at evoking a robust immune response against HIV-1. This breakthrough harnesses the latest advancements in immunology to craft immunogens that elicit broadly neutralizing antibodies in humans, a significant stride in HIV-1 therapeutic and preventive strategies.

The technology pertains to a novel polymer nanoparticle platform designed for the creation of individualized cancer vaccines. It utilizes a two-component system that combines patient-specific peptide neoantigens with immunostimulants within self-assembling nanoparticles. This approach ensures the targeted delivery of neoantigens to the immune system, enhancing the immune response against cancer cells while avoiding the systemic activation often seen with conventional adjuvants.

The technology represents a groundbreaking approach to combatting adenovirus serotype 14 (Ad14) infections by employing a live attenuated Ad14 virus to induce a robust immune response in mammals. This method is designed to provide protection against severe infections and fatalities resulting from the emergence of Ad14 variants. Currently advancing through the Clinical Phase I stage of development, this innovative strategy holds significant promise in addressing a critical public health need for effective Ad14 vaccines.

The discovery involves the development of substituted phenylpyrrolecarboxamides as therapeutic agents for HIV-1 infection. These compounds target the Phe43 cavity of the HIV-1 gp120 protein, disrupting the interaction between gp120 and host cell receptors CD4 and CCR5/CXCR4, thereby inhibiting viral entry into host cells. This targeted approach presents a novel strategy for HIV therapy and prophylaxis, distinct from current treatments that target other stages of the viral life cycle.

This technology involves the screening of a library of 290 FDA-approved or clinically advanced compounds for their antiviral activity against Middle Eastern respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).

The Ribopuromycylation (RPM) technology, developed by Dr. Jon Yewdell and Dr. Alexandre David, offers a powerful and universal method for visualizing and studying protein translation within cells. RPM involves the use of puromycin, a molecule that mimics a tyrosyl-tRNA and terminates translation by becoming covalently incorporated into the nascent protein chain's C-terminus within the ribosome's A site. This technique enables the immobilization of puromycylated nascent protein chains on ribosomes when chain elongation inhibitors like cycloheximide or emetine are utilized.